全文获取类型
收费全文 | 2988篇 |
免费 | 229篇 |
出版年
2022年 | 13篇 |
2021年 | 31篇 |
2020年 | 18篇 |
2019年 | 15篇 |
2018年 | 32篇 |
2017年 | 23篇 |
2016年 | 57篇 |
2015年 | 80篇 |
2014年 | 99篇 |
2013年 | 207篇 |
2012年 | 147篇 |
2011年 | 158篇 |
2010年 | 97篇 |
2009年 | 96篇 |
2008年 | 144篇 |
2007年 | 173篇 |
2006年 | 139篇 |
2005年 | 141篇 |
2004年 | 162篇 |
2003年 | 159篇 |
2002年 | 126篇 |
2001年 | 110篇 |
2000年 | 107篇 |
1999年 | 91篇 |
1998年 | 32篇 |
1997年 | 30篇 |
1996年 | 27篇 |
1995年 | 23篇 |
1994年 | 25篇 |
1993年 | 35篇 |
1992年 | 71篇 |
1991年 | 58篇 |
1990年 | 49篇 |
1989年 | 45篇 |
1988年 | 41篇 |
1987年 | 45篇 |
1986年 | 34篇 |
1985年 | 38篇 |
1984年 | 32篇 |
1983年 | 23篇 |
1982年 | 15篇 |
1981年 | 22篇 |
1980年 | 12篇 |
1979年 | 15篇 |
1978年 | 14篇 |
1973年 | 12篇 |
1972年 | 11篇 |
1971年 | 11篇 |
1968年 | 10篇 |
1967年 | 12篇 |
排序方式: 共有3217条查询结果,搜索用时 15 毫秒
121.
H. Matsuo T. Takada K. Ichida T. Nakamura A. Nakayama Y. Takada 《Nucleosides, nucleotides & nucleic acids》2013,32(12):1098-1104
The ATP-binding cassette, subfamily G, member 2 gene ABCG2/BCRP locates in a gout-susceptibility locus (MIM 138900) on chromosome 4q. Recent genome-wide association studies also showed that the ABCG2 gene relates to serum uric acid levels and gout. Since ABCG2 is also known as a transporter of nucleotide analogs that are structurally similar to urate, and is an exporter that has common polymorphic reduced functionality variants, ABCG2 could be a urate secretion transporter and a gene causing gout. To find candidate mutations in ABCG2, we performed a mutation analysis of the ABCG2 gene in 90 Japanese patients with hyperuricemia and found six non-synonymous mutations. Among the variants, ATP-dependent urate transport was reduced or eliminated in five variants, and two out of the five variants (Q126X and Q141K) were frequently detected in patients. Haplotype frequency analysis revealed that there is no simultaneous presence of Q126X and Q141K in one haplotype. As Q126X and Q141K are a nonfunctional and half-functional haplotype, respectively, their genotype combinations are divided into four estimated functional groups. The association study with 161 male gout patients and 865 male controls showed that all of those who had dysfunctional ABCG2 had an increased risk of gout, and that a remarkable risk was observed in those with ≤1/4 function (OR, 25.8; 95% CI, 10.3–64.6; p = 3.39 × 10?21). In 2,150 Japanese individuals, the frequency of those with dysfunctional ABCG2 was more than 50%. Our function-based clinicogenetic analysis identified the combinations of dysfunctional variants of ABCG2 as a major contributing factor in Japanese patients with gout. 相似文献
122.
Hirotaka Matsuo Tappei Takada Kimiyoshi Ichida Takahiro Nakamura Akiyoshi Nakayama Hiroshi Suzuki 《Nucleosides, nucleotides & nucleic acids》2013,32(12):1117-1128
Recent genome-wide association studies showed that serum uric acid (SUA) levels relate to ABCG2/BCRP gene, which locates in a gout-susceptibility locus revealed by a genome-wide linkage study. Together with the ABCG2 characteristics, we hypothesized that ABCG2 transports urate and its dysfunction causes hyperuricemia and gout. Transport assays showed ATP-dependent transport of urate via ABCG2. Kinetic analysis revealed that ABCG2 mediates high-capacity transport of urate (Km: 8.24 ± 1.44 mM) even under high-urate conditions. Mutation analysis of ABCG2 in 90 Japanese hyperuricemia patients detected six nonsynonymous mutations, including five dysfunctional variants. Two relatively frequent dysfunctional variants, Q126X and Q141K, were then examined. Quantitative trait locus analysis of 739 Japanese individuals showed that Q141K increased SUA as the number of minor alleles of Q141K increased (p = 6.60 × 10?5). Haplotype frequency analysis revealed that there is no simultaneous presence of Q126X and Q141K in one haplotype. Becuase Q126X and Q141K are assigned to nonfunctional and half-functional haplotypes, respectively, their genotype combinations are divided into four functional groups. The association study with 161 male gout patients and 865 male controls showed that all of those with dysfunctional ABCG2 increased the gout risk, especially those with ≤1/4 function (OR, 25.8; 95% CI, 10.3–64.6; p = 3.39 × 10?21). These genotypes were found in 10.1% of gout patients, but in only 0.9% of control. Our function-based clinicogenetic (FBCG) analysis showed that combinations of the two dysfunctional variants are major causes of gout, thereby providing a new approach for prevention and treatment of the gout high-risk population. 相似文献
123.
Takuya Nakayama Margaret B. Fish Marilyn Fisher Jamina Oomen‐Hajagos Gerald H. Thomsen Robert M. Grainger 《Genesis (New York, N.Y. : 2000)》2013,51(12):835-843
We have assessed the efficacy of the recently developed CRISPR/Cas (clustered regularly interspaced short palindromic repeats/CRISPR‐associated) system for genome modification in the amphibian Xenopus tropicalis. As a model experiment, targeted mutations of the tyrosinase gene were verified, showing the expected albinism phenotype in injected embryos. We further tested this technology by interrupting the six3 gene, which is required for proper eye and brain formation. Expected eye and brain phenotypes were observed when inducing mutations in the six3 coding regions, as well as when deleting the gene promoter by dual targeting. We describe here a standardized protocol for genome editing using this system. This simple and fast method to edit the genome provides a powerful new reverse genetics tool for Xenopus researchers. genesis 51:835–843. © 2013 Wiley Periodicals, Inc. 相似文献
124.
Sachiko N. Isobe Hideki Hirakawa Shusei Sato Fumi Maeda Masami Ishikawa Toshiki Mori Yuko Yamamoto Kenta Shirasawa Mitsuhiro Kimura Masanobu Fukami Fujio Hashizume Tomoko Tsuji Shigemi Sasamoto Midori Kato Keiko Nanri Hisano Tsuruoka Chiharu Minami Chika Takahashi Tsuyuko Wada Akiko Ono Kumiko Kawashima Naomi Nakazaki Yoshie Kishida Mitsuyo Kohara Shinobu Nakayama Manabu Yamada Tsunakazu Fujishiro Akiko Watanabe Satoshi Tabata 《DNA research》2013,20(1):79-92
125.
126.
127.
Jun Kojima Jun Araya Hiromichi Hara Saburo Ito Naoki Takasaka Kenji Kobayashi Satoko Fujii Chikako Tsurushige Takanori Numata Takeo Ishikawa Kenichiro Shimizu Makoto Kawaishi Keisuke Saito Noriki Kamiya Jun Hirano Makoto Odaka Toshiaki Morikawa Hiroshi Hano Satoko Arai Toru Miyazaki Yumi Kaneko Katsutoshi Nakayama Kazuyoshi Kuwano 《Respiratory research》2013,14(1):30
Background
Marked accumulation of alveolar macrophages (AM) conferred by apoptosis resistance has been implicated in pathogenesis of chronic obstructive pulmonary disease (COPD). Apoptosis inhibitor of macrophage (AIM), has been shown to be produced by mature tissue macrophages and AIM demonstrates anti-apoptotic property against multiple apoptosis-inducing stimuli. Accordingly, we attempt to determine if AIM is expressed in AM and whether AIM is involved in the regulation of apoptosis in the setting of cigarette smoke extract (CSE) exposure.Methods
Immunohistochemical evaluations of AIM were performed. Immunostaining was assessed by counting total and positively staining AM numbers in each case (n = 5 in control, n = 5 in non-COPD smoker, n = 5 in COPD). AM were isolated from bronchoalveolar lavage fluid (BALF). The changes of AIM expression levels in response to CSE exposure in AM were evaluated. Knock-down of anti-apoptotic Bcl-xL was mediated by siRNA transfection. U937 monocyte-macrophage cell line was used to explore the anti-apoptotic properties of AIM.Results
The numbers of AM and AIM-positive AM were significantly increased in COPD lungs. AIM expression was demonstrated at both mRNA and protein levels in isolated AM, which was enhanced in response to CSE exposure. AIM significantly increased Bcl-xL expression levels in AM and Bcl-xL was involved in a part of anti-apoptotic mechanisms of AIM in U937 cells in the setting of CSE exposure.Conclusions
These results suggest that AIM expression in association with cigarette smoking may be involved in accumulation of AM in COPD. 相似文献128.
Kenichi Tanaka Masaaki Nakayama Makoto Kanno Hiroshi Kimura Kimio Watanabe Yoshihiro Tani Yuki Kusano Hodaka Suzuki Yoshimitsu Hayashi Koichi Asahi Keiji Sato Toshio Miyata Tsuyoshi Watanabe 《PloS one》2013,8(12)
Background
Advanced glycation end product (AGE) accumulation is thought to be a measure of cumulative metabolic stress that has been reported to independently predict cardiovascular disease in diabetes and renal failure. The aim of this study was to evaluate the association between AGE accumulation, measured as skin autofluorescence, and the progression of renal disease in pre-dialysis patients with chronic kidney disease (CKD).Methods
Skin autofluorescence was measured noninvasively with an autofluorescence reader at baseline in 449 pre-dialysis patients with CKD. The primary end point was defined as a doubling of serum creatinine and/or need for dialysis.Results
Thirty-three patients were lost to follow-up. Forty six patients reached the primary end point during the follow-up period (Median 39 months). Kaplan-Meier analysis showed a significantly higher risk of development of the primary end points in patients with skin autofluorescence levels above the optimal cut-off level of 2.31 arbitrary units, derived by receiver operator curve analysis. Cox regression analysis revealed that skin autofluorescence was an independent predictor of the primary end point, even after adjustment for age, gender, smoking history, diabetes, estimated glomerular filtration rate and proteinuria (adjusted hazard ratio 2.58, P = 0.004).Conclusions
Tissue accumulation of AGEs, measured as skin autofluorescence, is a strong and independent predictor of progression of CKD. Skin autofluorescence may be useful for risk stratification in this group of patients; further studies should clarify whether AGE accumulation could be one of the therapeutic targets to improve the prognosis of CKD. 相似文献129.
130.